M Peeters1, J Balfour, D Arnold. 1. Department of Hepatogastroenterology, Digestive Oncology Unit, University Hospital Ghent, Gent, Belgium. marc.peeters@ugent.be
Abstract
BACKGROUND:Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR). AIM: To review the efficacy of panitumumab in the treatment of metastatic colorectal cancer (mCRC). METHODS: Available literature identified from PubMed and conference websites was reviewed. RESULTS: In phase 2-3 studies, panitumumab monotherapy achieved objective response rates (ORRs) of 8-13% in relapsed/refractory EGFR-expressing mCRC. In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). Objective response was achieved in 22/231 (10%) patients randomized to panitumumab--and also in 20/176 (11%) patients assigned to the control group who received panitumumab in a separate crossover protocol after disease progression. Response was confined to patients with tumours harbouring wild-type KRAS (ORR approximately equal to 20%). Panitumumab is also being evaluated in earlier lines of treatment. Panitumumab monotherapy is generally well tolerated; the most common toxicities are skin toxicity (approximately equal to 90%) and diarrhoea (<30%). Development of anti-panitumumab antibodies (0.3% by ELISA) and grade 3-4 infusion reactions (<1%) are rare. CONCLUSION:Panitumumab is an effective monotherapy option for patients with relapsed/refractory EGFR-expressing mCRC harbouring wild-type KRAS.
RCT Entities:
BACKGROUND:Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR). AIM: To review the efficacy of panitumumab in the treatment of metastatic colorectal cancer (mCRC). METHODS: Available literature identified from PubMed and conference websites was reviewed. RESULTS: In phase 2-3 studies, panitumumab monotherapy achieved objective response rates (ORRs) of 8-13% in relapsed/refractory EGFR-expressing mCRC. In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). Objective response was achieved in 22/231 (10%) patients randomized to panitumumab--and also in 20/176 (11%) patients assigned to the control group who received panitumumab in a separate crossover protocol after disease progression. Response was confined to patients with tumours harbouring wild-type KRAS (ORR approximately equal to 20%). Panitumumab is also being evaluated in earlier lines of treatment. Panitumumab monotherapy is generally well tolerated; the most common toxicities are skin toxicity (approximately equal to 90%) and diarrhoea (<30%). Development of anti-panitumumab antibodies (0.3% by ELISA) and grade 3-4 infusion reactions (<1%) are rare. CONCLUSION:Panitumumab is an effective monotherapy option for patients with relapsed/refractory EGFR-expressing mCRC harbouring wild-type KRAS.
Authors: Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl Journal: MAbs Date: 2009 Nov-Dec Impact factor: 5.857
Authors: Ralf Lutterbuese; Tobias Raum; Roman Kischel; Patrick Hoffmann; Susanne Mangold; Benno Rattel; Matthias Friedrich; Oliver Thomas; Grit Lorenczewski; Doris Rau; Evelyne Schaller; Ines Herrmann; Andreas Wolf; Thomas Urbig; Patrick A Baeuerle; Peter Kufer Journal: Proc Natl Acad Sci U S A Date: 2010-06-28 Impact factor: 11.205
Authors: Giovanni Simone; Anita Mangia; Andrea Malfettone; Vincenza Rubini; Michele Siciliano; Anna Di Benedetto; Irene Terrenato; Flavia Novelli; Marcella Mottolese Journal: J Exp Clin Cancer Res Date: 2010-09-15